DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive interim results from its ongoing Open-Label ...

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...

DBV announced that the FDA lifted a partial clinical hold on its phase 3 study of DBV712. The product is a patch intended for use in kids with peanut allergies. The FDA placed DBV Technologies' phase ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...

DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants issued in its March 2025 financing, resulting in the creation of tens of ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European ...

DBV Technologies S.A. (NASDAQ: DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.

Châtillon, France, February 9, 2025DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech SummitDBV Technologies ...

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of ...